Why the study?
Does acute genetic ablation of pendrin lower blood pressure in a transgenic mouse model?
Does acute genetic ablation of pendrin lower blood pressure in a transgenic mouse model?
Acute genetic ablation of pendrin significantly lowers blood pressure in mice without altering acid-base or potassium levels, suggesting it as a potential novel target for hypertension.
Answers are grounded in this paper and cite their sources.
Inducible pendrin mouse model enables targeted volume studies; leaves open clinical relevance for human hypertension.
BACKGROUND: Pendrin, the chloride/bicarbonate exchanger of β-intercalated cells of the renal connecting tubule and the collecting duct, plays a key role in NaCl reabsorption by the distal nephron. Therefore, pendrin may be important for the control of extracellular fluid volume and blood pressure. METHODS: Here, we have used a genetic mouse model in which the expression of pendrin can be switched-on in vivo by the administration of doxycycline. Pendrin can also be rapidly removed when doxycycline administration is discontinued. Therefore, our genetic strategy allows us to test selectively the acute effects of loss of pendrin function. RESULTS: We show that acute loss of pendrin leads to a significant decrease of blood pressure. In addition, acute ablation of pendrin did not alter significantly the acid-base status or blood K + concentration. CONCLUSION: By using a transgenic mouse model, avoiding off-target effects related to pharmacological compounds, this study suggests that pendrin could be a novel target to treat hypertension.
No takes yet. Share an insight, caveat, or question.
Trepiccione et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: